JP2006516630A - 抗凝固処理全血から産生される自己又は同種の凝固剤 - Google Patents
抗凝固処理全血から産生される自己又は同種の凝固剤 Download PDFInfo
- Publication number
- JP2006516630A JP2006516630A JP2006503054A JP2006503054A JP2006516630A JP 2006516630 A JP2006516630 A JP 2006516630A JP 2006503054 A JP2006503054 A JP 2006503054A JP 2006503054 A JP2006503054 A JP 2006503054A JP 2006516630 A JP2006516630 A JP 2006516630A
- Authority
- JP
- Japan
- Prior art keywords
- whole blood
- thrombin
- coagulant
- anticoagulated
- acd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Ecology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
Abstract
Description
ACD acid−citrate−dextrose
(酸性キトレートデキストロース)
CaCl2 塩化カルシウム
CPD citrate−phosphate−dextrose
(キトレートリン酸デキストロース)
EDTA エチレンジアミン四酢酸
ETOH エタノール、エチルアルコール
PEG ポリエチレングリコール
PPP patelet−poor plasma(乏血小板血漿)
PRP patelet−rich plasma(多血小板血漿)
PC patelet concentrate(濃縮血小板)
「抗凝固剤」という用語は、全血の凝固を防止することのできる物質を意味している。
「自己血」という用語は、患者自身の血液を意味している。
「同種血」という用語は、凝固剤を調製する個人以外の血液提供者から得られる血液を意味している。
「凝固剤」という用語は、全血又は血液成分(血漿、血小板)が凝血塊を形成させることができる物質を意味している。
a)供血者から1容量の抗凝固処理された全血を得ること
b)沈殿剤と抗凝固処理された全血とを混合すること
c)前記b)の混合物を細胞及び特定の血漿成分の沈殿を起こすために充分な時間、インキュベートすること
d)前記c)で得られた沈殿を上清から分離すること(通常、遠心分離及び/又は濾過)、及び
e)凝固剤として使用する上清を回収すること
を含む。
実施例1
[放射性免疫拡散法の手順]
《上清中のヘモグロビンの測定》
《自己のトロンビンによる濃縮血小板と乏血小板血漿の凝固時間の比較》
[濃縮血小板の凝固時間の比較]
[精製ヒトフィブリノーゲンの異なる濃度での凝固時間]
[フィブリノーゲン検査]
《組織培養実験》
1.濃縮血小板及びウシトロンビン;
2.濃縮血小板及び自己トロンビン;及び
3.濃縮血小板及び自己凝固促進剤
[ヒト間葉幹細胞の培養]
対照群と試験混合物に1時間暴露処理した群では、細胞の形態又は密度に変化はなかった。BTの上清との接触後24時間培養した群では、核の高密度化(dense)を伴った細胞の球形化が見られた。ATで処理した群の細胞の形態は、対照群と同様であった。
《成長因子分泌の動態》
・ ストッパー付のガラス又はプラスチックチューブ
・ 血清フィルターシステム、例えば、血清分離器具、沈殿から上清を吸引する ために最適な平滑なカニューレ、又はピペットシステム。
・ 平滑な針のついた3mLの注射筒
・ 平滑な針のついた10mLの注射筒
・ ACD又はACD/マンニトールを含んだバイアル
・ ETOH/CaCl2を含んだバイアル
・ TrayPak(商標)と説明書
1.それは、全血検体から調製することができる。
2.調製の工程の反応は室温で行うことができる
3.工程は、SMARTPREP(商標)systemを使用して、血小板濃縮と 同時に又は独立して調製することができる。
4.全血と沈殿剤の反応時間は45分か、又はそれ未満である
5.得られた自己凝固剤の調製物は、濃縮血小板又は乏血小板血漿を臨床的に許容 可能な時間内に凝固させる十分な濃度(strength)がある。
6.自己凝固剤は、濃縮血小板又は乏血小板血漿と伴に、様々な方法や器具で提供 されることができる。
7.本発明の自己凝固剤は、直接創傷部位(wound bed)に適用すること ができる。
Hematol. 1994 ; 45: 128.
2. Fastenau DR and McIntyre. Immunochemical analysis of polyspecific antibodies in patients exposed to bovine fibrin sealant. Ann. Thorac. Surg. 2000; 69: 1867.
3. Banninger H, Hardegger I, Tobler A et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br.
J. Haematol. 1993; 85: 528.
4. Streiff MB and Ness PM. Acquired factor V inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002 ; 42: 18.
5. Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelism with heparin−induced thrombocytopenia.
Thrombosis and Haemostasis 1996; 75: 536.
6. Sands JJ, Nudo SA, Ashford RG, et al. Antibodies to topical bovine thrombin correlate with access thrombosis. Am. J. Kid. Dis. 2000; 45: 796.
7. Gottumukkala VNR, Sharma SK. and Philip J. Assessing platelet and fibrinogen contribution to clot strength using modified thromboelastography in pregnant women. Anesth. Analg. 1999; 89: 1453 8. Babbush CA, Kevy SV and Jacobson MS. An in vitro and in vivo evaluation of autologous platelet concentrate in oral reconstruction. Implant Dentistry 2003 ; 12: 24.
9. Lee SJ. Cytokine delivery and tissue engineering. Yonsei Medical Journal 2000; 41: 704 10. Slater M, Patava J, Kingham K, et al. Involvement of platelets in stimulating osteogenic activity. J. Orthop. Res. 1995; 13: 655 11. Haynesworth SE, Kadiyala S, Liang LN, et al. Chemotactic and mitogenic stimulation of human mesenchymal stem cells by platelet rich plasma suggests a mechanism for enhancement of bone repair. 48th Annual Meeting Orthopedic Research Society, Dallas, TX, 2002.
Claims (20)
- 抗凝固処理した全血から凝固剤を製造する方法であって、
a)対象から1容量の抗凝固処理した全血を得ること
b)前記抗凝固処理した全血と沈殿剤とを混合すること
c)前記b)の混合物を細胞及び特異的血漿成分の沈殿物、並びに上清を産生するのに十分な時間インキュベートすること
d)上清から沈殿物を分離すること、及び
e)凝固剤として使用する前記上清を回収すること、
を含む方法。 - 前記抗凝固処理した全血の容量が、8〜10mLである、請求項1に記載の方法。
- 前記全血をACD、ACD/マンニトール、CPD、及びEDTAからなる群から選択される抗凝固剤で抗凝固処理する請求項1に記載の方法。
- 前記全血を酸性キトレートデキストロースで抗凝固処理する請求項3に記載の方法。
- 前記全血をACD/マンニトールで抗凝固処理する請求項3に記載の方法。
- 前記マンニトールが7.5mg/mLACDの濃度で含まれている請求項5に記載の方法。
- 前記沈殿剤がエタノールである請求項1に記載の方法。
- 使用する前記エタノールが、約10%〜100%の開始濃度である請求項7に記載の方法。
- 使用する前記エタノールが、約25%〜95%の開始濃度である請求項8に記載の方法。
- 使用する前記エタノールが、約50%から95%の開始濃度である請求項9に記載の方法。
- 前記沈殿剤がエタノールと塩化カルシウムとの混合物である請求項1に記載の方法。
- 前記インキュベート工程が45分未満を要する請求項1に記載の方法。
- 前記インキュベート工程が30分未満を要する請求項1に記載の方法。
- 調製される前記凝固剤が自己である請求項1に記載の方法。
- 調製される前記凝固剤が同種である請求項1に記載の方法。
- 前記分離工程が混合物を遠心することによって行われる請求項1に記載の方法。
- 前記分離工程が混合物を濾過することによって行われる請求項1に記載の方法。
- 前記分離工程が混合物の遠心及び濾過の組み合わせによって行われる請求項1に記載の方法。
- 抗凝固処理した全血からの凝固剤の調製用のキットであって、
a)ストッパー付のチューブ;
b)血清濾過分離器;
c)平滑針付き3mLの注射筒;
d)平滑針付き10mLの注射筒;
e)ACD又はACD/マンニトールを含むバイアル;
f)EtOH/CaCl2を含むバイアル;及び
g)説明書
を含むキット。 - 請求項1に記載の方法によって製造されるヒト血液画分であって、プロトロンビン−トロンビンタンパク質80−90%を含み、検出可能なフィブリノーゲンを含まず、及びATIII、プロテインC、及びプロテインSの基準値レベル20−30%を含むヒト血液画分。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44297403P | 2003-01-27 | 2003-01-27 | |
PCT/US2004/002191 WO2004068109A2 (en) | 2003-01-27 | 2004-01-27 | Autologous or homologous coagulant produced from anticoagulated whole blood |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006516630A true JP2006516630A (ja) | 2006-07-06 |
JP2006516630A5 JP2006516630A5 (ja) | 2007-02-08 |
Family
ID=32825282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006503054A Pending JP2006516630A (ja) | 2003-01-27 | 2004-01-27 | 抗凝固処理全血から産生される自己又は同種の凝固剤 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20040208786A1 (ja) |
EP (1) | EP1599715A2 (ja) |
JP (1) | JP2006516630A (ja) |
KR (1) | KR20050105184A (ja) |
CN (2) | CN101317855A (ja) |
AU (1) | AU2004207261B2 (ja) |
BR (1) | BRPI0406931A (ja) |
CA (1) | CA2514001A1 (ja) |
IL (1) | IL169792A0 (ja) |
MX (1) | MXPA05007888A (ja) |
WO (1) | WO2004068109A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020506880A (ja) * | 2017-02-09 | 2020-03-05 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 出血の処置または予防における使用のための血液凝固因子代替製品 |
WO2023047832A1 (ja) * | 2021-09-27 | 2023-03-30 | 国立大学法人 東京大学 | 細胞培養用成分、細胞培養用培地、血清の製造方法、及び、細胞の製造方法 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060094865A1 (en) * | 2004-10-29 | 2006-05-04 | Kapur Terri A | Intraoperative method for isolating and concentrating autologous growth factors and for forming residual autologous growth factor compositions |
WO2008129551A1 (en) * | 2007-04-18 | 2008-10-30 | H2Q Water Industries Ltd. | Filter medium |
EP2625263B1 (en) | 2010-10-08 | 2020-03-11 | Terumo BCT, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
US9962480B2 (en) * | 2012-01-23 | 2018-05-08 | Estar Technologies Ltd | System and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma (PRP) |
RU2589648C2 (ru) * | 2012-09-25 | 2016-07-10 | Стем Селл Партнерс Ллк | Способ и устройство для получения сыворотки с тромбином от одного донора |
WO2015073918A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
EP3122866B1 (en) | 2014-03-25 | 2019-11-20 | Terumo BCT, Inc. | Passive replacement of media |
EP3198006B1 (en) | 2014-09-26 | 2021-03-24 | Terumo BCT, Inc. | Scheduled feed |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
EP3464565A4 (en) | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | CELL EXPANSION |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
EP3656842A1 (en) | 2017-03-31 | 2020-05-27 | Terumo BCT, Inc. | Cell expansion |
US20220088589A1 (en) | 2019-01-21 | 2022-03-24 | Eclipse Medcorp, Llc | Methods, Systems and Apparatus for Separating Components of a Biological Sample |
CN110361531B (zh) * | 2019-08-02 | 2023-04-11 | 天津医科大学总医院 | 一种检测微粒促凝活性的实验方法 |
US12007382B2 (en) | 2019-10-31 | 2024-06-11 | Crown Laboratories, Inc. | Systems, methods and apparatus for separating components of a sample |
CN112841171A (zh) * | 2021-01-12 | 2021-05-28 | 广州鸿泉生物科技有限公司 | 用于血栓试验中的抗凝猪血、猪血浆的制备方法及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10212236A (ja) * | 1997-01-02 | 1998-08-11 | Haemonetics Corp | 濃縮赤血球の調製における抗凝固及び保存用溶液 |
WO2000007659A1 (en) * | 1998-08-05 | 2000-02-17 | Thermogenesis Corp. | Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby |
WO2000074713A1 (en) * | 1999-06-04 | 2000-12-14 | Thermogenesis Corp. | Autologous thrombin |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4359463A (en) * | 1980-11-26 | 1982-11-16 | Rock Gail A | Stabilization of Factor VIII activity in whole blood or blood plasma |
EP0107688B1 (en) * | 1982-04-28 | 1986-10-01 | The Trustees Of The Garfield Weston Trust For Research Into Heart Surgery | Processes for the production of blood products |
US4675385A (en) * | 1985-03-27 | 1987-06-23 | Alpha Therapeutic Corporation | Isolation of human plasma procoagulant protein factor VIII from biological factors |
JPS6360931A (ja) * | 1986-08-29 | 1988-03-17 | Noboru Sato | 血液または血液製剤保存液およびこれを用いた血液または血液製剤の保存方法 |
US5135875A (en) * | 1990-08-15 | 1992-08-04 | Abbott Laboratories | Protein precipitation reagent |
SE9403833D0 (sv) * | 1994-11-08 | 1994-11-08 | Global Hemostasis Inst Mgr Ab | Analysförfarande och kit |
US5510102A (en) * | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US6320029B1 (en) * | 1996-11-29 | 2001-11-20 | The American National Red Cross | Methods of production and use of liquid formulations of plasma proteins |
AU2941297A (en) * | 1996-05-24 | 1997-12-09 | Thermogenesis Corp. | Fibrinogen apparatus, method and container |
US5783447A (en) * | 1996-10-02 | 1998-07-21 | University Of Medicine And Dentistry Of New Jersey | Hypercoagulability comparative determinants obtained using detection systems with variable force-induced energy inputs |
US20020082220A1 (en) * | 2000-06-29 | 2002-06-27 | Hoemann Caroline D. | Composition and method for the repair and regeneration of cartilage and other tissues |
AU2002359918A1 (en) * | 2001-12-28 | 2003-07-24 | Terumo Kabushiki Kaisha | Blood bag system and method of inactivating pathogenic microorganisms |
US20040120942A1 (en) * | 2002-12-23 | 2004-06-24 | Mcginnis Daniel | Device and process for the preparation of autologous thrombin serum |
-
2004
- 2004-01-27 CN CNA2008101304992A patent/CN101317855A/zh active Pending
- 2004-01-27 US US10/765,694 patent/US20040208786A1/en not_active Abandoned
- 2004-01-27 WO PCT/US2004/002191 patent/WO2004068109A2/en active Application Filing
- 2004-01-27 EP EP04705602A patent/EP1599715A2/en not_active Withdrawn
- 2004-01-27 AU AU2004207261A patent/AU2004207261B2/en not_active Ceased
- 2004-01-27 BR BR0406931-5A patent/BRPI0406931A/pt not_active IP Right Cessation
- 2004-01-27 KR KR1020057013816A patent/KR20050105184A/ko not_active Application Discontinuation
- 2004-01-27 CN CNB2004800083526A patent/CN100415093C/zh not_active Expired - Fee Related
- 2004-01-27 MX MXPA05007888A patent/MXPA05007888A/es active IP Right Grant
- 2004-01-27 CA CA002514001A patent/CA2514001A1/en not_active Abandoned
- 2004-01-27 JP JP2006503054A patent/JP2006516630A/ja active Pending
-
2005
- 2005-07-20 IL IL169792A patent/IL169792A0/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10212236A (ja) * | 1997-01-02 | 1998-08-11 | Haemonetics Corp | 濃縮赤血球の調製における抗凝固及び保存用溶液 |
WO2000007659A1 (en) * | 1998-08-05 | 2000-02-17 | Thermogenesis Corp. | Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby |
WO2000074713A1 (en) * | 1999-06-04 | 2000-12-14 | Thermogenesis Corp. | Autologous thrombin |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020506880A (ja) * | 2017-02-09 | 2020-03-05 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 出血の処置または予防における使用のための血液凝固因子代替製品 |
JP7227905B2 (ja) | 2017-02-09 | 2023-02-22 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 出血の処置または予防における使用のための血液凝固因子代替製品 |
WO2023047832A1 (ja) * | 2021-09-27 | 2023-03-30 | 国立大学法人 東京大学 | 細胞培養用成分、細胞培養用培地、血清の製造方法、及び、細胞の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1764372A (zh) | 2006-04-26 |
AU2004207261A1 (en) | 2004-08-12 |
WO2004068109A3 (en) | 2005-10-27 |
MXPA05007888A (es) | 2005-12-15 |
CN101317855A (zh) | 2008-12-10 |
IL169792A0 (en) | 2007-07-04 |
US20040208786A1 (en) | 2004-10-21 |
AU2004207261B2 (en) | 2009-07-09 |
CA2514001A1 (en) | 2004-08-12 |
WO2004068109A2 (en) | 2004-08-12 |
KR20050105184A (ko) | 2005-11-03 |
EP1599715A2 (en) | 2005-11-30 |
CN100415093C (zh) | 2008-09-03 |
BRPI0406931A (pt) | 2006-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006516630A (ja) | 抗凝固処理全血から産生される自己又は同種の凝固剤 | |
EP2491961B1 (en) | Composition for inducing tissue regeneration by activating platelet-rich plasma (prp), and method for manufacturing same | |
JP4860857B2 (ja) | 自己由来トロンビン | |
Seegers | Prothrombin | |
Rickles et al. | Tissue factor activity in lymphocyte cultures from normal individuals and patients with hemophilia A | |
Deykin | Uremic bleeding | |
Inceman et al. | Aggregation, adhesion, and viscous metamorphosis of platelets in congenital fibrinogen deficiencies | |
Arora et al. | Quantification of platelets and platelet derived growth factors from platelet-rich-plasma (PRP) prepared at different centrifugal force (g) and time | |
JP2896235B2 (ja) | 局所フィブリノーゲン複合体 | |
JP2004500026A5 (ja) | ||
US20060039991A1 (en) | Biological tissue regenerative agent and method for preparing and using same | |
Honig et al. | Deficiency of Hageman factor (factor XII) in patients with the nephrotic syndrome | |
Waaler | A simple one-stage method for the assay of antihemophilic A factor with a comment on the plasma level of this factor in hemophilia A | |
Johnson et al. | Use of purified prothrombin in the study of hemophilia and plasma thromboplastin component (PTC) deficiency | |
Düregger et al. | Autologous fibrin glue: Automated production and adhesive quality | |
Amris et al. | Infusion of porcine plasmin in man. Studies on toxicology and pharmacodynamics | |
Canoso et al. | The Hemostatic Defect of Chronic Liver Disease: Kinetic Studies Using 75Se-Selenomethionine | |
Ratnoff | The blood clotting mechanism and its disorders | |
US20060039990A1 (en) | Biological tissue regenerative agent and method for preparing same | |
Hahn et al. | Evaluation of the in vivo antithrombotic, anticoagulant and fibrinolytic activities of Lumbricus rubellus earthworm powder | |
Watanabe et al. | Platelet antithrombins: Role of thrombin binding and the release of platelet fibrinogen | |
Ehrenworth | Spontaneously occurring anticoagulant against antihemophilic globulin in a previously normal subject | |
Edson | Hemophilia, von Willebrand's disease, and related conditions: A spectrum of laboratory and clinical disorders | |
Ende et al. | Activation of a fibrinolytic system in a dog with mast cell tumor | |
Khalifa | Determination of Oral Contraceptive pills Effect on Coagulation Profile among Sudanese women in Shendi locality |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061212 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061212 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061212 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100608 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100903 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100910 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101008 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101018 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110222 |